Effectiveness of treatment for 31 patients with seropositive autoimmune autonomic ganglionopathy in Japan.

"we excluded questions related to the vasomotor and pupillomotor domains because judging skin color changes in japanese patients is occasionally difficult on an individual basis and wearing sunglasses or tinted glasses in japan is not customary for middle-aged and older people (mcompass; supplementary data 1).; the frequencies of improvement in autonomic symptoms pre- and post-immunotherapy were as follows: oh (77 4% and 64 5% respectively) oi (87 1% and 64 5% respectively) sicca (54 8% and 43 5% respectively) and lower gastrointestinal dysfunctions (83 9% and 67 7% respectively; supplementary data 2-1 ).; in terms of extra-autonomic manifestations endocrine symptoms improved (12 9% and 3 2% respectively; supplementary data 2-1 ).; the following mcompass items showed improvement from pre- and post-treatment: oi (mcompass3 6 7 +/- 0 8 5 7 +/- 0 8 respectively; mcompass4 5 5 +/- 0 8 0 9 +/- 0 4 respectively) dry mouth (mcompass7 1 2 +/- 0 2 0 7 +/- 0 2; mcompass8 1 9 +/- 0 3 1 2 +/- 0 2 respectively) vomiting (mcompass13 0 4 +/- 0 1 0 2 +/- 0 1 respectively) diarrhea (mcompass15 0 6 +/- 0 2 0 3 +/- 0 1 respectively; mcompass16 0 5 +/- 0 1 0 1 +/- 0 1 respectively) constipation (mcompass20 0 9 +/- 0 2 0 5 +/- 0 1 respectively) and urinary disturbance (mcompass22 1 0 +/- 0 2 0 8 +/- 0 2 respectively) ( supplementary data 2-2 ).; clinical features were observed in the immunotherapy effective group and immunotherapy ineffective group based on the respective clinical profile ( supplementary data 3-1 ) and mcompass results ( supplementary data 3-2 )."

"Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Ministry of Health, Labor, and Welfare, Japan and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (JSPS KAKENHI Grant Number 19H03549) and AMED under Grant Number 21dk 0310099."